Please assess the completion status of the following clinical trial:

Trial Title: Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with melanoma based on International Classification of Disease 9th and 10th Revisions (ICD-9: 172.x; ICD-10: C43x, D03x) and ≥2 visits on different days in the Flatiron database on or after January 1, 2011.~* Clinically confirmed diagnosis of melanoma with pathologic stages III or IV at initial diagnosis or earlier stage disease with a first locoregional or distant recurrence on or after January 1, 2011.~* Age ≥18 years at the time of advanced melanoma diagnosis.~* Evidence of ≥1 BRAF positive test result at any time based on laboratory or genetic analysis results.~Exclusion Criteria:~-• Patients with prior BRAF- or MEK-inhibitor therapy~• Patients with ECOG performance status ≥ 2 (at the time of randomization for patients from COLUMBUS, during the baseline period for patients in Flatiron EHR)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Encorafenib + binimetinib (Type: None): Encorafenib 450 mg once a day (QD) Binimetinib 45 mg twice a day (BID)
- Vemurafenib + Cobimetinib (Type: None): Vemurafenib 960 mg twice a day (BID) for 28 days of 28 day cycle Cobimetinib 60 mg once a day (QD) for 21 days of 28 day cycle
- Dabrafenib + trametinib (Type: None): Dabrafenib 150 mg twice a day (BID) Trametinib 2 mg once a day (QD)

Based on this trial design, predict the completion outcome and termination type (if applicable).